Friday, 15 July 2016

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H1 2016

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted pipeline therapeutics.
The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics development and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) 
- The report reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) 
- Devise corrective measures for pipeline projects by understanding Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
BioMAS Ltd. Biotest AG enGene, Inc Intrexon Corporation LEO Pharma A/S Merck & Co., Inc. P2D Bioscience Pfizer Inc. SK Biopharmaceuticals Co., Ltd.

Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

Recent Report on Multiple Sclerosis - Pipeline Review, H1 2016

Multiple Sclerosis - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Multiple Sclerosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development,mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete report with TOC available @ ​Multiple Sclerosis - Pipeline Review, H1 2016.
Scope
- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Companies Mentioned
4D Pharma Plc 4SC AG AB Science SA AbbVie Inc. Ablynx NV Acorda Therapeutics, Inc. Actelion Ltd Addex Therapeutics Ltd Adhaere Pharmaceuticals, Inc. Aegis Therapeutics, LLC Affectis Pharmaceuticals AG AiCuris GmbH & Co. KG Alkermes Plc Alpha Cancer Technologies Inc. Amarna Therapeutics B.V. Anavex Life Sciences Corp. Antisense Therapeutics Limited Antitope Limited Aphios Corporation Apitope International NV Arena Pharmaceuticals, Inc. Argos Therapeutics, Inc. Arrien Pharmaceuticals, LLC Artielle ImmunoTherapeutics, Inc. Astellas Pharma Inc. Asterias Biotherapeutics, Inc. Atara Biotherapeutics, Inc. Athersys, Inc. Axxam SpA Baliopharm AG Bio-Cancer Treatment International Limited BioAegis Therapeutics, Inc. etc.

Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

Market Report covers Colon Cancer - Pipeline Review, H1 2016

Colon Cancer - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Colon Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
To access full report with TOC, please visit Colon Cancer - Pipeline Review, H1 2016.
Scope
- The report provides a snapshot of the global therapeutic landscape of Colon Cancer
- The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Colon Cancer
Reasons to buy
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned
ACF Pharmaceuticals, LLC Adgero Biopharmaceuticals, Inc. Aduro BioTech, Inc. Advanced Proteome Therapeutics Corporation Advenchen Laboratories, LLC Agenus, Inc. AGV Discovery, SAS AIMM Therapeutics B.V. Ambrx, Inc. Anavex Life Sciences Corp. AndroScience Corporation Aphios Corporation Aposense Ltd. Aptose Biosciences Inc. Asana BioSciences, LLC AstraZeneca Plc Aurigene Discovery Technologies Limited BCN Biosciences L.L.C. Bio-Path Holdings, Inc. Biogazelle Bioncotech Therapeutics S.L. Blirt S.A. Boehringer Ingelheim GmbH Can-Fite BioPharma Ltd. Celprogen, Inc. Celyad SA Chiome Bioscience, Inc. Critical Outcome Technologies Inc. Cyclacel Pharmaceuticals, Inc. CytomX Therapeutics, Inc. Cytune Pharma SAS CZ BioMed Corp DEKK-TEC, Inc. Digna Biotech, S.L. Eli Lilly and Company EntreChem, S.L. EnzymeBioSystems F. Hoffmann-La Roche Ltd. GlycaNova Norway AS Halozyme Therapeutics, Inc. Heat Biologics, Inc. Helix BioPharma Corp. Histogen, Inc. Horizon Pharma Plc Huperion Sarl Idera Pharmaceuticals, Inc.

Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

Research Study on Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
- The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
- Identify potential new clients or partners in the target demographic
Companies Mentioned
4SC AG AB Science SA AbbVie Inc. Ablynx NV Acceleron Pharma, Inc. Acetylon Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. Active Biotech AB Adaptimmune Therapeutics Plc Aduro BioTech, Inc. Affimed GmbH AIMM Therapeutics B.V. Altor BioScience Corporation Amgen Inc. Anthera Pharmaceuticals‚ Inc. APIM Therapeutics AS APO-T B.V. Arcarios BV Arno Therapeutics, Inc. Array BioPharma Inc. Arvinas, Inc. Asana BioSciences, LLC Astellas Pharma Inc. Astex Pharmaceuticals, Inc. Atara Biotherapeutics, Inc. Aurigene Discovery Technologies Limited Bellicum Pharmaceuticals, Inc. BioInvent International AB Biotest AG bluebird bio, Inc. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. Celgene Corporation Cell Source, Inc. etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

In-Depth Report on Dengue Fever - Pipeline Review, H1 2016

Dengue Fever - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Dengue Fever pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
To view the table of contents and know more details, please visit Dengue Fever - Pipeline Review, H1 2016.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dengue Fever
- The report reviews pipeline therapeutics for Dengue Fever by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dengue Fever
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned
Abivax S.A. Agilvax, Inc. Altravax, Inc. Arbovax, Inc. BCI Pharma Bioneer Corporation Biotron Limited CalAsia Pharmaceuticals, Inc. Cocrystal Pharma, Inc. Codagenix, Inc. Emergent BioSolutions Inc. Ennaid Therapeutics, LLC GlaxoSmithKline Plc Globavir Biosciences, Inc. Hawaii Biotech, Inc. Humabs BioMed SA Immunotope, Inc. Immunovaccine, Inc. Inovio Pharmaceuticals, Inc. Johnson & Johnson Kineta, Inc. Merck & Co., Inc. Molplex Ltd. NanoViricides, Inc. Novartis AG NovaTarg Therapeutics, Inc Panacea Biotec Limited ProtInhi B.V. Sanofi Pasteur SA Sarepta Therapeutics, Inc. SIGA Technologies, Inc. Takeda Pharmaceutical Company Limited TechnoVax, Inc. Themis Bioscience GmbH VaxInnate Corporation Visterra, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

Market Report Explored on Bacterial Pneumonia - Pipeline Review, H1 2016

Bacterial Pneumonia - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Bacterial Pneumonia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development,mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
To access full report with TOC, please visit ​Bacterial Pneumonia - Pipeline Review, H1 2016.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia
- The report reviews pipeline therapeutics for Bacterial Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Bacterial Pneumonia
Reasons to buy
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned
Abera Bioscience AB Actelion Ltd Alvogen Korea Co., Ltd. Aridis Pharmaceuticals LLC Arsanis Biosciences GmbH AstraZeneca Plc Beijing Minhai Biotechnology Co., Ltd ContraFect Corporation Daiichi Sankyo Company, Limited Double Bond Pharmaceutical International AB Emergent BioSolutions Inc. Eurocine Vaccines AB FluGen, Inc. GlaxoSmithKline Plc Humabs BioMed SA ImmunoBiology Limited Indian Immunologicals Limited Integrated BioTherapeutics, Inc. Kyorin Pharmaceutical Co., Ltd. Lascco SA LG Life Science LTD. Liquidia Technologies, Inc. MedImmune, LLC Merck & Co., Inc. Mucosis B.V. Noxxon Pharma AG Panacea Biotec Limited Prometheon Pharma, LLC Sanofi Pasteur SA Serum Institute of India Limited SK Chemicals Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Valneva SE Vaxxilon AG Virometix AG Walvax Biotechnology Co., Ltd. Wellstat Vaccines, LLC Wockhardt Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

Recent Analysis on Pertussis (Whooping Cough) - Pipeline Review, H1 2016

Pertussis (Whooping Cough) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Pertussis (Whooping Cough) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
To view the table of contents and know more details, please visit Pertussis (Whooping Cough) - Pipeline Review, H1 2016.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough)
- The report reviews pipeline therapeutics for Pertussis (Whooping Cough) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pertussis (Whooping Cough)
- Identify potential new clients or partners in the target demographic

Companies Mentioned
Beijing Minhai Biotechnology Co., Ltd Beijing Tiantan Biological Products Co., Ltd. Bharat Biotech International Limited Biological E. Limited Boryung Pharmaceutical Co., Ltd. Daiichi Sankyo Company, Limited DBV Technologies S.A. GlaxoSmithKline Plc Green Cross Corporation ILiAD Biotechnologies, LLC Indian Immunologicals Limited LG Life Science LTD. NanoBio Corporation Panacea Biotec Limited Sanofi Pasteur SA Serum Institute of India Limited Sinovac Biotech Ltd. Synthetic Biologics, Inc. Zydus Cadila Healthcare Limited

Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###